THE HAGUE

Aegon appoints Duncan Russell to succeed Matt Rider as Chief Financial Officer

Retrieved on: 
星期四, 五月 16, 2024

The Hague, May 16, 2024 - Aegon today announces the appointment of Duncan Russell (1978) as Chief Financial Officer (CFO), effective September 1, 2024.

Key Points: 
  • The Hague, May 16, 2024 - Aegon today announces the appointment of Duncan Russell (1978) as Chief Financial Officer (CFO), effective September 1, 2024.
  • Duncan will succeed Matt Rider (1963), who will retire after over seven years of exceptional service to the company.
  • Duncan Russell joined Aegon as Chief Transformation Officer in 2020.
  • Prior to Aegon, Duncan worked at UK-based Admiral Group Plc, where he last held the position of CFO of Admiral Financial Services.

Aegon trading update for first quarter 2024

Retrieved on: 
星期四, 五月 16, 2024

The Hague, May 16, 2024 - Please click here to access all 1Q2024 Trading Update related documents.

Key Points: 
  • The Hague, May 16, 2024 - Please click here to access all 1Q2024 Trading Update related documents.
  • Our joint venture in Brazil, Mongeral Aegon Group, continued its strong performance, with life sales increasing by 22% to EUR 28 million.
  • We expect the new program to start at the beginning of July 2024, and to complete it by the end of 2024.
  • Dial-in numbers for conference call:
    Annual General Meeting – June 12, 2024
    Aegon UK Strategy Teach-In (webinar) – June 25, 2024
    First half 2024 results – August 22, 2024
    Third quarter 2024 trading update – November 15, 2024

Aegon publishes agenda for 2024 Annual General Meeting

Retrieved on: 
星期三, 五月 8, 2024

The Hague, May 8, 2024 - Today, Aegon Ltd. publishes the agenda for its Annual General Meeting of Shareholders (AGM) to be held on Wednesday June 12, 2024.

Key Points: 
  • The Hague, May 8, 2024 - Today, Aegon Ltd. publishes the agenda for its Annual General Meeting of Shareholders (AGM) to be held on Wednesday June 12, 2024.
  • The agenda for the AGM also includes a proposal to adopt a new Director’s Remuneration Policy for the Non-Executive and Executive Directors.
  • During the meeting, it will be possible to raise questions related to the agenda either in person of via live chat or video connection for those shareholders attending the meeting virtually.
  • The terms of the Company’s policy regarding the hybrid meeting of shareholders will be applicable to the AGM.

Benelux Construction Equipment Market Assessment & Forecasts 2023-2024 & 2029: Rising Focus on Compact and Electric Construction Equipment and Focus on Green Transition Will Prompt Investments - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 30, 2024

In 2023, government investment in residential, road, and railways is expected to drive the demand for excavators in the Benelux construction equipment market during the forecast period.

Key Points: 
  • In 2023, government investment in residential, road, and railways is expected to drive the demand for excavators in the Benelux construction equipment market during the forecast period.
  • Earthmoving equipment accounted for the largest market share of the Benelux construction equipment market in 2023.
  • Rising interest rates and higher commodity prices may act as a barrier to the growth of the Benelux construction equipment market.
  • The rising focus on compact equipment in the Benelux construction equipment market is attributed to various factors, such as expanding urbanization, eco-friendly construction requirements, and off-road construction activities.

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World

Retrieved on: 
星期二, 四月 30, 2024

As a pioneer in the commercial application of probiotics in China, Ambpomial, a yogurt brand with a national reputation, was honored with an invitation to such a prestigious event as the Official Yogurt Provider.

Key Points: 
  • As a pioneer in the commercial application of probiotics in China, Ambpomial, a yogurt brand with a national reputation, was honored with an invitation to such a prestigious event as the Official Yogurt Provider.
  • With a world-first breakthrough, Ambpomial's ambient-stable yogurt has achieved a significant leap in the field of probiotic yogurt production by overcoming the long-standing technical challenge of probiotic inactivation in ambient yogurt, thus becoming a highlight of the forum.
  • Ambpomial has successfully incorporated 1 billion CFU of the globally renowned active probiotic strain, Lactobacillus rhamnosus GG, into each bottle of yogurt.
  • During the forum, Ambpomial invited a young scholar from China in probiotics to have on-site exchanges with European universities and probiotic companies.

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World

Retrieved on: 
星期二, 四月 30, 2024

As a pioneer in the commercial application of probiotics in China, Ambpomial, a yogurt brand with a national reputation, was honored with an invitation to such a prestigious event as the Official Yogurt Provider.

Key Points: 
  • As a pioneer in the commercial application of probiotics in China, Ambpomial, a yogurt brand with a national reputation, was honored with an invitation to such a prestigious event as the Official Yogurt Provider.
  • With a world-first breakthrough, Ambpomial's ambient-stable yogurt has achieved a significant leap in the field of probiotic yogurt production by overcoming the long-standing technical challenge of probiotic inactivation in ambient yogurt, thus becoming a highlight of the forum.
  • Ambpomial has successfully incorporated 1 billion CFU of the globally renowned active probiotic strain, Lactobacillus rhamnosus GG, into each bottle of yogurt.
  • During the forum, Ambpomial invited a young scholar from China in probiotics to have on-site exchanges with European universities and probiotic companies.

Aegon prices USD 760 million of senior unsecured notes

Retrieved on: 
星期三, 四月 10, 2024

The Hague, April 10, 2024 - Aegon has successfully priced USD 760 million of senior unsecured notes with a fixed coupon of 5.5% and a tenor of three years.

Key Points: 
  • The Hague, April 10, 2024 - Aegon has successfully priced USD 760 million of senior unsecured notes with a fixed coupon of 5.5% and a tenor of three years.
  • Net proceeds from this issuance will be used for general corporate purposes, including the previously announced redemption of the EUR 700 million of fixed-to-floating subordinated notes, effective as of April 25, 2024.
  • The notes are being issued by Aegon Funding Company LLC (AFC) and will be guaranteed on a senior unsecured basis by Aegon Ltd.
  • The notes are expected to be rated BBB+ and Baa1 by S&P Global and Moody's, respectively.

REMBRANDT - Etchings from the Boijmans Van Beuningen - A great master of the Dutch Golden Age is honoured in Québec City

Retrieved on: 
星期三, 四月 24, 2024

For Rembrandt, etching was a full-fledged art form equal to painting that he researched passionately throughout his career.

Key Points: 
  • For Rembrandt, etching was a full-fledged art form equal to painting that he researched passionately throughout his career.
  • The Museum Boijmans Van Beuningen, Rotterdam, in a nutshell
    The works in this exhibition are drawn from the celebrated print collection of the Museum Boijmans Van Beuningen in Rotterdam, founded in 1849.
  • The exhibition has been made possible by an exceptional loan of artworks from the Museum Boijmans Van Beuningen in Rotterdam, the Netherlands.
  • It has received financial support from the Québec government and Québec City under the Agreement on Cultural Development.

Clinical Microbiomics Launches Advanced Long-Read 16S, ITS, 18S, Isolate, and Metagenomics Sequencing Services

Retrieved on: 
星期二, 四月 23, 2024

COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics, a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services. Tailored to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities, featuring the industry's highest quality scores and read lengths.

Key Points: 
  • COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics , a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services.
  • Anders Grøn, CEO, states, "Our enhanced long-read sequencing capabilities are redefining the standards in microbial analysis and microbiome research.
  • Dr. Henrik Bjørn Nielsen , Chief Scientific Officer, states, "Our new long-read sequencing services represent a significant advancement in microbiome research.
  • Clinical Microbiomics' long-read sequencing services are globally available, supported by state-of-the-art laboratories in Denmark and the United States.

BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS

Retrieved on: 
星期二, 四月 23, 2024

MINNEAPOLIS, April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.

Key Points: 
  • Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications.
  • RNAscope is the most referenced technology in the industry, with its rapidly growing portfolio of peer-reviewed publications recently surpassing 10,000.
  • In its lawsuit filed in the Unified Patent Court (a pan-European forum for resolving patent disputes), in the Netherlands Local Division of the Court of First Instance in The Hague, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439.
  • The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing ACD's patents in key European markets.